As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kura Oncology Inc. The largest reported stake is Bvf Partners L P's, at 9.99%. 11 filings are on record since August 14, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Kura Oncology Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 7,763,592 · Shared voting: 0 · Sole dispositive: 7,908,832 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Montanova Capital, LLC · Sole voting: 0 · Shared voting: 8,575,422 · Sole dispositive: 0 · Shared dispositive: 8,575,422 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 3,736,000 · Sole dispositive: 0 · Shared dispositive: 3,736,000 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: Vanguard Capital Management · Sole voting: 643,127 · Shared voting: 0 · Sole dispositive: 4,428,812 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-30
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Kura Oncology Inc has 11 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bvf Partners L P | 9.99% | 8,677,018 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Montanova Capital, LLC | 9.7% | 8,575,422 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 8.9% | 7,908,832 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| State Street Corporation | 5.7% | 4,931,090 | SCHEDULE 13G, 2026-02-09 | 2025-12-31 |
| Vanguard Capital Management | 5.01% | 4,428,812 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| EcoR1 Capital, LLC | 4.8% | 4,200,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Armistice Capital, LLC | 4.23% | 3,736,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Kura Oncology Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Kura Oncology Inc and the records around it.
Kura Oncology Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Montanova Capital, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Kura Oncology Inc
Get an email when Kura Oncology Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kura Oncology Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kura Oncology Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kura Oncology Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Montanova Capital, LLC | 0 | 8,575,422 | 0 | 8,575,422 | SCHEDULE 13G/A, 2026-08-14 |
| Averill Master Fund, Ltd. | 0 | 7,805,540 | 0 | 7,805,540 | SCHEDULE 13G/A, 2026-08-14 |
| Aaron Cowen | 0 | 8,575,422 | 0 | 8,575,422 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 7,763,592 | 0 | 7,908,832 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Vanguard Capital Management | 643,127 | 0 | 4,428,812 | 0 | SCHEDULE 13G, 2026-04-30 |
| Armistice Capital, LLC | 0 | 3,736,000 | 0 | 3,736,000 | SCHEDULE 13G/A, 2026-05-15 |
| Steven Boyd | 0 | 3,736,000 | 0 | 3,736,000 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Kura Oncology Inc by CUSIP 50127T109 and gives its principal executive office as 4930 Directors Place, Suite 500, SAN DIEGO, CA 92121 (SCHEDULE 13G/A, 2026-10-27).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | EcoR1 Capital, LLC | 4.8% | SCHEDULE 13G/A |
| 2025-08-15 | Armistice Capital, LLC | 7.14% | SCHEDULE 13G/A |
| 2025-11-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 5.37% | SCHEDULE 13G/A |
| 2026-02-09 | State Street Corporation | 5.7% | SCHEDULE 13G |
| 2026-02-17 | Armistice Capital, LLC | 5.67% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Vanguard Capital Management | 5.01% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 4.23% | SCHEDULE 13G/A |
| 2026-08-14 | Montanova Capital, LLC | 9.7% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 8.9% | SCHEDULE 13G/A |
Questions about who owns Kura Oncology Inc
Who owns Kura Oncology Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Kura Oncology Inc: Bvf Partners L P (9.99%, Schedule 13G/A, filed 2025-11-14), Montanova Capital, LLC (9.7%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (8.9%, Schedule 13G/A, filed 2026-10-27), State Street Corporation (5.7%, Schedule 13G, filed 2026-02-09) and Vanguard Capital Management (5.01%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Kura Oncology Inc?
By the share each holder's latest filing reports, the largest holders of Kura Oncology Inc on this page are Bvf Partners L P (9.99%), Montanova Capital, LLC (9.7%) and BlackRock, Inc. (8.9%).
When did Bvf Partners L P buy into Kura Oncology Inc?
The filings give report dates, not purchase dates. The earliest filing from Bvf Partners L P on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Kura Oncology Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 8, 2026 | Leadership change: Jennifer Fulk appointed, Chief Financial Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Kura Oncology Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.